// App-Quantinova.ai

AB0939 (2018) : Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study

Researchers

Presenter

  • M. Phung

Principal Investigators

  • A. Ighani

  • J.R. Georgakopoulos

  • R. Vender

  • L. Giroux

  • P. Lansang

  • J. Yeung

Medical Centers

  • Department of Pharmacology and Toxicology,

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

  • Division of Dermatology, Department of Medicine, McMaster University, Hamilton

  • Department of Dermatology, The Northern Ontario School of Medicine, Sudbury

  • Division of Dermatology, Sunnybrook Health Sciences Centre

  • Division of Rheumatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

  • Probity Clinical Research, Waterloo, ON, Canada

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved